Pharmaceutical Technology1h
RioDerm-002 by Rion for Radiation Injury: Likelihood of Approval
RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
Pharmaceutical Technology8h
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.
Pharmaceutical Technology19h
Trientine hydrochloride by Innolife for Systolic Heart Failure: Likelihood of Approval
Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% ...
Pharmaceutical Technology23h
LM-302 by Bristol-Myers Squibb for Esophageal Cancer: Likelihood of Approval
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition ...
Pharmaceutical Technology23h
Vemurafenib by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have ...
Pharmaceutical Technology23h
Vemurafenib by F. Hoffmann-La Roche for Sarcomas: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate ...